Group 1: Robotics Sector - The robotics concept stocks experienced a broad increase, with notable gains from companies like XAG (02590) up 5.93%, Yunji (02670) up 5.10%, and Blues Technology (06613) up 4.82%. According to an Omdia report, the global annual installation of humanoid robots is expected to add approximately 16,000 units by 2025, with Zhiyuan Robotics leading the market in installations [1][2] - Tianyue Advanced (02631) surged over 15.8% as a report from Zheshang Securities highlighted its active expansion into silicon carbide applications in emerging fields, indicating long-term growth potential [1] - WeRide (00800) rose over 3.4% as it announced that its global Robotaxi fleet will reach 1,000 vehicles by January 12, 2026, with successful commercial operations in cities like Guangzhou, Beijing, and Abu Dhabi [1] - Cao Cao Mobility (02643) increased nearly 8% following its announcement of two strategic acquisitions, including a full acquisition of Weixing Technology and plans to acquire Geely Business Travel [1] Group 2: Energy and Materials Sector - Oil and gas stocks saw significant declines, with Shandong Molong (00568) dropping over 8.1% due to a sharp decrease in international oil prices, with Brent crude futures falling by $2.76 or 4.15% to $63.76 per barrel [2] - Innovation Industry (02788) rose nearly 8% as aluminum prices have surged significantly since 2026, with Huatai Securities indicating that the overall supply-demand tightness will continue, supporting a long-term profit increase in the aluminum sector [2] Group 3: Aerospace and Technology Sector - The commercial aerospace sector showed signs of recovery, with companies like Asia Pacific Satellite (01045) and JunDa Co. (02865) both rising by 5.02%. This follows Elon Musk's announcement that SpaceX aims to increase Starship launch frequency to over once per hour within three years [2] - Weichai Power (02338) increased over 4.9% as it announced advancements in solid-state battery research and strong demand for its power generation products [3] - Zhaoyi Innovation (03986) rose over 6.2% as a Counterpoint Research report indicated that the memory market has entered a "super bull market," surpassing historical highs from 2018 [4] Group 4: US Market Highlights - Nuclear power stocks strengthened, with Talen Energy (TLN.US) up 11.8% and Vistra Energy (VST.US) up 6.63%, following news of a new bipartisan bill proposing a $2.5 billion Strategic Resilience Reserve to secure key minerals domestically [5] - Morgan Stanley (MS.US) rose 5.78% after reporting Q4 revenue growth of 10% to $17.89 billion, exceeding market expectations [5] - The weight loss drug sector faced pressure, with Eli Lilly (LLY.US) down 3.76% as its weight loss drug was placed under FDA review, delaying a decision until April 2026 [6] - Dell Technologies (DELL.US) increased by 0.82% as Omdia reported a significant recovery in the global PC market, with a projected 9.2% increase in total shipments for 2025 [8]

Group 1: Acquisition Details - Boston Scientific announced a definitive agreement to acquire Penumbra for $374 per share, corresponding to an enterprise value of approximately $14.5 billion [2] - The transaction will be completed through a combination of cash and stock, with cash accounting for about 73% and stock for about 27% [2] - The cash portion will be financed through internal funds and new debt, with the deal expected to close in 2026 pending shareholder approval [2] Group 2: Penumbra's Business Overview - Penumbra, based in Alameda, California, focuses on thrombosis-related diseases and neurovascular interventions, with a projected revenue of approximately $1.4 billion for 2025, reflecting a year-on-year growth of about 17% [3] - The company's products address various critical conditions, including acute ischemic stroke, pulmonary embolism, deep vein thrombosis, acute limb ischemia, myocardial infarction, and aneurysm-related interventions [3] Group 3: Technological Strategy - Penumbra's strategy centers on mechanical thrombectomy rather than drug thrombolysis or energy-assisted methods, with its most recognizable technology being the Computer-Assisted Vacuum Thrombectomy (CAVT) system [4] - The Lightning Bolt and Lightning Flash product series enhance operational consistency and controllability in complex clinical scenarios, such as pulmonary embolism and peripheral deep vein thrombosis [6] Group 4: Complementary Product Lines - Penumbra has developed a peripheral embolization system for rapid blood flow intervention in scenarios requiring hemorrhage control or vascular occlusion, complementing its thrombectomy systems [7] - This dual product line allows Penumbra to address both "thrombus removal" and "blood flow blockage" needs, enhancing its market position [7] Group 5: Industry Context - The acquisition of Penumbra is part of a broader trend of adjacent expansion in the vascular intervention field by large medical device companies, focusing on extending existing customer bases and clinical pathways [13] - Boston Scientific previously established a market presence in the peripheral vascular and pulmonary embolism sectors through its EKOS product line, which utilizes ultrasound-assisted thrombolysis [14][16] Group 6: Strategic Implications - The acquisition is viewed as a means to complement Boston Scientific's existing product offerings rather than replace them, as it addresses different stages in the stroke treatment continuum [16][18] - The recent acquisition of Inari Medical by Stryker has raised the profile of the peripheral thrombosis and pulmonary embolism markets, leading to a reassessment of growth potential and valuation for companies like Penumbra [19][20]

Core Viewpoint - Penumbra Inc. is set to be acquired by Boston Scientific Corp. in a deal valued at approximately $14.5 billion, which is expected to enhance Boston Scientific's portfolio in cardiovascular and neurovascular therapies [2][5] Group 1: Acquisition Details - Boston Scientific's acquisition offer values Penumbra at $374 per share, representing a 19% premium over its previous closing price [2][5] - The transaction will be financed with 73% cash and 27% stock, with Boston Scientific planning to fund the $11 billion cash portion through cash reserves and new debt [3] - Penumbra shareholders can choose between receiving $374 in cash or 3.87 shares of Boston Scientific stock [3] Group 2: Market Reactions - Following the acquisition announcement, Penumbra's shares surged nearly 12% to around $350, while Boston Scientific's shares declined by 4.5% to approximately $90 [4] - The boards of both companies have approved the transaction, which is expected to close in 2026, pending Penumbra shareholder approval [4] Group 3: Analyst Ratings - BTIG downgraded Penumbra from a Buy to a Neutral rating after the acquisition announcement, reflecting investor caution despite the premium offered [1][5]

Group 1: Financial Developments - Penumbra's shares surged nearly 12% to around $350 following the announcement of its acquisition by Boston Scientific, which values Penumbra at $374 per share and approximately $14.5 billion in enterprise value [2][5] - Wells Fargo has set a price target of $374 for Penumbra, indicating a 6.47% increase from its current trading price of $351.27, but downgraded the stock to Equal Weight from Overweight [1][5] Group 2: Acquisition Details - Under the acquisition agreement, Penumbra shareholders can choose to receive either $374 in cash or 3.87 shares of Boston Scientific stock for each share they hold, with the total consideration being approximately 73% cash and 27% stock [3][5] - Boston Scientific plans to finance the $11 billion cash portion of the acquisition using cash on hand and new debt, with the transaction expected to close in 2026, pending shareholder approval [3] Group 3: Stock Performance - Penumbra's stock has experienced a significant increase of 12.07%, translating to a rise of $37.85, with today's trading volume at 6,385,647 shares [4] - The stock fluctuated between a low of $345.20 and a high of $352.15, marking its highest point for the year, while the lowest price over the past year was $221.26 [4]

NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask: About Monteverde & Associates PC NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Penumbra ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Boston Scientific has agreed to acquire Penumbra in a cash-and-stock deal worth $14.5 billion. ...

Core Viewpoint - Boston Scientific (BSX) is acquiring Penumbra (PEN) for $14.5 billion, or $374 per share, which will enhance Boston Scientific's presence in the cardiovascular sector [1] Group 1: Acquisition Details - The acquisition price of $14.5 billion represents a significant investment for Boston Scientific [1] - Penumbra specializes in mechanical thrombectomy and neurovascular fields, focusing on treatments for conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, and heart-related issues [1] Group 2: Market Reaction - Following the announcement, Boston Scientific's shares experienced a decline before the market opened, while Penumbra's stock saw an increase [1]

Merger Investigations - Penumbra, Inc. is set to be acquired by Boston Scientific Corporation in a cash and stock transaction valuing Penumbra at $374 per share, with an enterprise value of approximately $14.5 billion. The investigation focuses on whether the Penumbra Board breached its fiduciary duties by failing to conduct a fair process and whether the deal provides fair value to shareholders [2] - Calavo Growers, Inc. will be acquired by Mission Produce, Inc., with Calavo stockholders receiving $27.00 per share, consisting of $14.85 in cash and 0.9790 shares of Mission for each share of Calavo. The total enterprise value of the transaction is approximately $430 million. The investigation examines if the Calavo Board breached its fiduciary duties regarding the fairness of the deal [4] - Clearwater Analytics Holdings, Inc. is being acquired by a Permira and Warburg Pincus-led Investor Group for $24.55 per share in cash, amounting to approximately $8.4 billion. The investigation looks into whether the Clearwater Analytics Board failed to conduct a fair process and if the deal consideration is fair for shareholders [6]

MILWAUKEE, Jan. 15, 2026 /PRNewswire/ -- Ademi LLP is investigating Penumbra (NYSE: PEN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Boston Scientific. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.  There is no cost or obligation to you. In the transaction, Penumbra stockholders can elect to receive $374 in cash or 3.8721 shares of Boston Sc ...